Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

Summary

The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want to find out if this combination of Regorafenib and Nivolumab can help people with metastatic colorectal cancer with mismatch repair (MMR) proficiency.

Timeline

Start

2018-10-23

Primary completion

2021-09-01

Completion

2024-01-18

Publications

• Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC, Kim DW. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022 Jul;169:93-102. doi: 10.1016/j.ejca.2022.03.026. Epub 2022 May 5.

Drugs

Indications